Chosa Oncology Past Earnings Performance
Past criteria checks 0/6
Chosa Oncology has been growing earnings at an average annual rate of 41.1%, while the Biotechs industry saw earnings growing at 10.1% annually.
Key information
41.1%
Earnings growth rate
49.9%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -37.3% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Chosa Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -7 | -8 | 0 |
| 31 Mar 24 | 0 | -9 | 8 | 0 |
| 31 Dec 23 | 0 | -24 | 9 | 0 |
Quality Earnings: W5L is currently unprofitable.
Growing Profit Margin: W5L is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if W5L's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare W5L's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: W5L is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.6%).
Return on Equity
High ROE: W5L has a negative Return on Equity (-37.34%), as it is currently unprofitable.